RxDoctor Payments Data

Suzette Killeen, MD

Ophthalmology · Marrero, LANPI 1699774935

Payments from drug & device makers

$4,696in general payments, 2019–2025

Across 249 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$644
  • Oyster Point Pharma, Inc.$445
  • Bausch & Lomb Americas Inc.$392
  • Sun Pharmaceutical Industries Inc.$374
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$276
  • plus $987 from 13 others

What the payments were for

  • Food & beverage$4,696100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,696 in reported general payments places this provider in the 75th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$154,852
Medicare patients
469
Services billed
1,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost130$55,830
CombiganBrimonidine Tartrate/Timolol113$46,384
Alphagan PBrimonidine Tartrate125$42,934
RocklatanNetarsudil Mesylat/Latanoprost75$35,454
RestasisCyclosporine29$31,275
MieboPerfluorohexyloctane/Pf32$24,944
Lotemax SmLoteprednol Etabonate73$17,907
VyzultaLatanoprostene Bunod37$17,525
SimbrinzaBrinzolamide/Brimonidine Tart40$11,400
Brimonidine Tartrate190$10,325
Travoprost62$8,213
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$5,996
Timolol Maleate135$4,009
Dorzolamide-TimololDorzolamide/Timolol/Pf18$3,845
Fluorometholone50$3,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$1,578$176,423397 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$392$42,46969 claims
Aerie Pharmaceuticals, Inc.Rocklatan$157$35,45475 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$276$17,90773 claims
AlconSimbrinza$644$11,40040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →